Cluster of Differentiation 19 (CD19)

Where the papers sit

29 papers from the last 6 months study Cluster of Differentiation 19 (CD19) directly · updated from PubMed 8 Oct 2026

• CAR Therapy for B-Cell Lymphoma

  Relapsed or refractory B-cell lymphoma is moving toward more accessible and more potent cellular therapies, including allogeneic and point-of-care manufactured products. CD19 CAR-T remains central, while CD19/20 and CD19/20/22 trispecific designs and CAR-NK cells seek broader targeting and scalable delivery. Complete responses are reported alongside neutropenia and respiratory viral infections, making immune recovery a recurring endpoint. Spatial profiling and low-strength type I interferon studies are beginning to connect tumor context and T-cell state with efficacy.

  11 papers · 37.9%

• CD19-Targeted Immune Therapy

  B-ALL treatment is shifting toward CD19-directed immune consolidation, with CAR-T and blinatumomab tested against relapse, chemotherapy exposure and transplant-era risk. Comparative profiling and pretransplant studies focus on complete remission, relapse, disease-free survival and the trade-off between durable control and immune toxicity. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remain important liabilities, including catastrophic cerebral edema with blinatumomab. CD19 CAR-T is also expanding into pemphigus vulgaris and myasthenia gravis, but the leukemia and autoimmune evidence remains clinically separate.

  10 papers · 34.5%

• Programmable CAR-T Engineering

  CAR-T development is moving from single-antigen designs toward programmable cells that can recognize, equip or activate against otherwise difficult tumors. Ultrasound gating, universal tumor-antigen delivery and multiplex base editing aim to improve spatial control, persistence and resistance to tumor heterogeneity. BCL-2 targeting during cell manufacture is used to enhance potency through adaptive, non-apoptotic changes, while CD179a designs extend testing in B-cell malignancies. Evidence is predominantly preclinical, with spheroid and animal systems supporting feasibility rather than established clinical benefit.

  5 papers · 17.2%

• CAR-NK Therapy for Lupus

  Refractory systemic lupus erythematosus, particularly lupus nephritis, is being approached with allogeneic CD19 CAR-NK cells rather than escalating conventional immunosuppression. Low-dose cord-blood products with 4-1BB co-stimulation are intended to deplete pathogenic B cells while improving safety and access. Reports track lupus nephritis, arthritis, Lupus Low Disease Activity State and 2021 DORIS remission criteria, with hints of durable immune resetting. Evidence remains limited to early clinical experience, leaving durability, relapse and long-term safety unresolved.

  3 papers · 10.3%